Non-toxic cross-linker for hyaluronic acid

1. A method for cosmetic augmentation, comprising:

characterizing a target tissue,

maintaining a consistency of a biocompatible polymer in particle size and population density to match the target tissue by forming the biocompatible polymer with an average molecular weight and a polydispersity index;

storing a non-toxic biocompatible cross-linker;

storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of a selected pharmaceutical substance to modulate soft tissue response to the polymer;

mixing the biocompatible cross-linker and polymer into a mixture and cross-linking the polymer; and reversibly cross-linking the polymer, where the cross links are labile at high pH values, and at physiological pH, the cross-links become fixed;

augmenting soft tissue with the biocompatible cross-linked polymer having a predetermined radiolucency greater than silicone or saline radiolucency; and

releasing the selected pharmaceutical substance over time to modulate soft tissue response to the polymer.

2. The method of claim 1 , comprising introducing the polymer into a breast implant shell of a soft tissue human implant prior to or during implantation of the shell with a lumen in a human body.

3. The method of claim 1 , comprising cross-linking the polymer, wherein a cross linking reaction occurs outside the shell or in-situ inside a breast implant shell.

4. The method of claim 1 , wherein the polymer comprises one of: collagens, PEG, hyaluronic acids, celluloses, proteins, saccharides, biodegradable and bioresorbable biocompatible materials.

5. The method of claim 1 , wherein the polymer comprises an extracellular matrix of a biological system.

6. The method of claim 1 , comprising using cross linkers and forming homo-polymers or to form copolymers by crosslinking with other polymer species.

7. The method of claim 1 , comprising adding a substance to the composition for biocompatibility.

8. The method of claim 1 , comprising controlling drug releases at predetermined timing in anticipation of an onset of a negative physiological event in response to an invading foreign bodies.

9. The method of claim 1 , comprising fast releasing, medium or slow releasing the composition.

10. The method of claim 1 , comprising adding anesthetics, lidocaine or compound to reduce or eliminate acute inflammatory reactions to the pharmaceutical substance.

11. The method of claim 1 , comprising adding one or more compositions selected from the group consisting of steroids, corticosteroids, dexamethasone, triamcinolone.

12. The method of claim 1 , comprising providing an antiproliferative compound.

13. The method of claim 1 , wherein the substance comprises paclitaxel, sirolimus.

14. The method of claim 1 , comprising controlling a scar formation process around a foreign body including capsular formation.

15. The method of claim 1 , comprising optimizing degradation profile of the composition.

16. The method of claim 1 , comprising minimizing migration of the composition.

17. A method for cosmetic augmentation, comprising:

maintaining a consistency of a biocompatible polymer in particle size and population density by forming the biocompatible polymer with an average molecular weight and a polydispersity index;

storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of a selected pharmaceutical substance to modulate soft tissue response to the polymer;

mixing the biocompatible cross-linker and polymer into a mixture and augmenting soft tissue with the biocompatible polymer;

reversibly cross-linking the polymer, where the cross links are labile at high pH values, and at physiological pH, the cross-links become fixed;

releasing the selected pharmaceutical substance over time to modulate soft tissue response to the polymer; and

modeling a 3D model of a human body and continuously updating a display with a current shape of breast or butt from the 3D model including the injection to show fit to a desired shape.

18. The method of claim 1 , comprising co-cross-linking glycosaminoglycan chemically with at least one other polymer including hyaluronan or hylan.

19. The method of claim 1 , wherein the chemically cross-linked glycosaminoglycan is hyaluronan or hylan.

20. The method of claim 1 , comprising in-situ non-covalent bonding including one of: hydrogen association, charge or ionic interactions, pH, osmolality.

21. A method for cosmetic augmentation, comprising:

maintaining a consistency of a biocompatible polymer in particle size and population density to match a target tissue by forming the biocompatible polymer with an average molecular weight and a polydispersity index;

storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of a selected pharmaceutical substance to modulate soft tissue response to the polymer;

mixing the biocompatible cross-linker and polymer into a mixture and augmenting soft tissue with the biocompatible polymer;

releasing the selected pharmaceutical substance over time to modulate soft tissue response to the polymer; and

modeling a 3D model of a human body and continuously updating a display with a current shape of breast or butt from the 3D model including the injection to show fit to a desired shape.

22. The method of claim 1 , comprising injecting with a mechanical pump the biocompatible crosslinked polymer under soft tissue in a minimally invasive manner.

23. A method for cosmetic augmentation, comprising:

storing a non-toxic biocompatible cross-linker;

storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer;

mixing the biocompatible cross-linker and polymer and injecting the mixture into a patient and reversibly cross-linking the polymer, where the cross links are labile at high pH values, and at physiological pH, the cross-links become fixed;

augmenting soft tissue with the biocompatible cross-linked polymer having a predetermined radiolucency greater than silicone or saline radiolucency; and

releasing the selected pharmaceutical substance over time to modulate soft tissue response to the polymer.